术前他汀治疗与胸主动脉腔内修复术后5年生存率升高相关
基于血管质量倡议(VQI)2014至2020年前瞻性数据,纳入6266例胸主动脉腔内修复(TEVAR)患者,经倾向评分匹配后分析发现,术前他汀使用与较低的围手术期并发症率和5年死亡率相关(18.8% vs 24.5%;HR 0.74;95%CI 0.63-0.89;择期TEVAR和动脉瘤患者中该关联显著,而急诊/紧急TEVAR中未达统计学意义。
要点
- 择期TEVAR和动脉瘤患者中5年死亡率显著降低,急诊/紧急TEVAR中无统计学意义。
核心结论
- 术前他汀治疗与TEVAR患者较低的围手术期并发症率和5年死亡率相关。
- 已知胸主动脉病变患者除非有禁忌,均应接受他汀治疗。
- 择期TEVAR的他汀处方率可作为质量指标,并需进一步实施研究改善术前他汀使用。
研究设计与样本
- 回顾性分析血管质量倡议(VQI)2014至2020年前瞻性收集的TEVAR患者数据。
- 排除年龄<18岁、创伤及使用定制或医生修改器械的患者。
- 纳入6266例患者,其中3331例(53%)术前使用他汀。
- 采用倾向评分匹配患者特征、合并症、病理和紧急程度,匹配后每组1875例。
- 使用逻辑回归和Cox回归分析短期和5年结局。
关键数值与推荐
- 动脉瘤疾病患者中术前他汀使用比例为64%(1148/2267)。
临床怎么用
- 对已知胸主动脉病变患者,除非有禁忌,应给予他汀治疗。
- 择期TEVAR术前他汀处方率可作为质量指标。
- 需进一步实施研究以提高术前他汀使用率。
局限性
- 研究为回顾性分析,尽管采用倾向评分匹配,仍可能存在未测量混杂。
- 急诊/紧急TEVAR和夹层等亚组中他汀关联未达统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statin use is associated with higher long-term survival after abdominal aortic aneurysm repair. However, the association between statin use and survival after thoracic endovascular aortic repair (TEVAR) has not been established. METHODS: We performed a review of prospectively collected data of all patients who had undergone TEVAR in the Vascular Quality Initiative between 2014 and 2020. We excluded patients aged <18 years, those who had presented with trauma, and those who had received custom-manufactured or physician-modified devices. We evaluated the association between preoperative statin therapy and in-hospital mortality and complications and 5-year mortality. We also analyzed the trend of preoperative statin use in elective cases for the previous 7 years. To account for nonrandom assignment to treatment, we used propensity score matching of patient characteristics, comorbidities, pathology, and urgency for preoperative statin use. We used logistic regression and Cox regression for the short-term and 5-year outcomes, respectively. RESULTS: Of 6266 patients who had undergone TEVAR and met the inclusion criteria, 3331 (53%) patients had been taking a statin preoperatively, including 1148 of 2267 (64%) treated for aneurysmal disease. After propensity score matching, 1875 patients were in each cohort. Preoperative statin use was associated with lower rates of any perioperative complication (16.7% vs 19.6%; odds ratio, 0.82; 95% confidence interval [CI] 0.69-0.97; P = .022). Overall, preoperative statin use was also associated with lower 5-year mortality (18.8% vs 24.5%; hazard ratio [HR], 0.74; 95% CI, 0.63-0.89; P = .001). When stratified by urgency, preoperative statin use was associated with lower 5-year mortality after elective TEVAR (14.9% vs 22.4%; HR, 0.62; 95% CI, 0.49-0.79; P < .001) but not after urgent or emergent TEVAR (27.4% vs 29.1%; HR, 0.89; 95% CI, 0.70-1.14; P = .37). When stratified by pathology, preoperative statin use was associated with significantly lower 5-year mortality for patients with aneurysms (HR, 0.63; 95% CI, 0.48-0.83; P = .001). Although the mortality was also lower for patients with dissection and "other" pathology, these differences did not reach statistical significance. Between 2014 and 2019, a significant increase had occurred in statin use among patients undergoing elective TEVAR, from 56% in 2014 to 64% in 2019 (P = .007). CONCLUSIONS: Preoperative statin therapy is associated with lower perioperative complication rates and 5-year mortality for patients undergoing TEVAR. All patients with known thoracic aortic pathology should receive statin therapy unless contraindications for the drug are present. For patients undergoing elective TEVAR, the statin prescription percentage should be considered a quality metric, and further implementation research should occur to improve preoperative statin use.
引用
- Allar BG, Swerdlow NJ, de Guerre LEVM, et al. Preoperative statin therapy is associated with higher 5-year survival after thoracic endovascular aortic repair. J Vasc Surg. 2021. PMID: 34182025. doi:10.1016/j.jvs.2021.05.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。